{"organizations": [], "uuid": "0c5939c67a8cd82fc3b7637153d27b6f191b8177", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-ekso-bionicsa-to-report-first-quarter-2018-financial-results-on-may-7-2018.html", "country": "US", "domain_rank": 767, "title": "Ekso Bionics® to Report First Quarter 2018 Financial Results on May 7, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.006, "site_type": "news", "published": "2018-04-30T16:00:00.000+03:00", "replies_count": 0, "uuid": "0c5939c67a8cd82fc3b7637153d27b6f191b8177"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-ekso-bionicsa-to-report-first-quarter-2018-financial-results-on-may-7-2018.html", "ord_in_thread": 0, "title": "Ekso Bionics® to Report First Quarter 2018 Financial Results on May 7, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "richmond", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "ekso bionics holdings", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "RICHMOND, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2018 after the close of trading on Monday, May 7, 2018. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.\nInvestors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers, using Conference ID: 13581989. A live webcast of the event will be available in the “Investors” section of the company’s website at www.eksobionics.com , or by clicking here .\nA replay of the call will be available for two weeks by dialing (877) 660-6853 for domestic callers or (201) 612-7415 for international callers, using Conference ID: 13581989. The webcast will also be available on the company’s website for one month following the completion of the call.\nAbout Ekso Bionics ®\nEkso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com .\nMedia Contact:\nChantal Beaudry\n212-867-1762\ncbeaudry@lazarpartners.com\nInvestor Contact:\nDavid Carey\n212-867-1768\ninvestors@eksobionics.com\nSource:Ekso Bionics Holdings, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=GPoaVnCLzM9DwqWvHiAAiMDa5Zur_5IXy-3wc8azVVrriIgDK5jy_1qrmQ_3tXV5BURYPd5aXRUImNVA6LczuX6Aqj9AQRsSoPNPouKsmmXJvLQwRk9AnHpAQJSM4m6y", "https://www.globenewswire.com/Tracker?data=-LsB3er5UXkOOQXgT4Fd2gWCD1Ma-Ws2FcePKCHuJ5HHyy07FFlAyHcEQzLVAKQeeMenAdjrkfyIzaYzgWIG6n85JbOlCaEU_JgDVhbi8XU=", "https://www.globenewswire.com/Tracker?data=CpGq5dujDy3yfzciJijhMlwTST-Pt3xL8_8mfFTJVlfEG677mxjtXUMJVfqy1ihezSXSud_7be3C7MupKQ5O-V9GWlaEPDrfZuhvGDE8ETPJXfst2RdTXkRr38BgI48Ewin2BFiMsDpNDP_Fnz6m3SQYN3o8H2sckY212R0UdAA=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/b8eb3344-76d5-498f-a377-85b7a2d47c60", "https://www.globenewswire.com/Tracker?data=SwEbHVvArLZkdcijCvOxDeA6fLetsmcRRc0u_lsnHL3mXcwR2IYNgv_RJTp-U3aBlRgcno9TN_JGZUnp2zfOq0cJZudaCmjzVFHhf6Cqwkk=", "https://www.globenewswire.com/Tracker?data=SwEbHVvArLZkdcijCvOxDdn-hs4YRw5JOjFscynId0-QP-eFSp7RyeKDjNosNyUjGFSzXp1ZEQPZBkpKocs8JeqO72umyXpfhvLvGDRgltNenVRQ3CD_O42PFe0kytNXOYvAIHkTkamhKQJmqQUvmZWG8qdQWdm6UajdRofN_mBy3-ZZ01Dx9aW4GD95s7bNxG4WMRHDthDS90Dk1yZcltW4oPugFDu-gkDnw08-lbw8TVZWUuP4K1PrzqbUF5nG"], "published": "2018-04-30T16:00:00.000+03:00", "crawled": "2018-04-30T18:16:01.001+03:00", "highlightTitle": ""}